StreetInsider.com News Articles

B.Riley on Ovid Therapeutics Inc (OVID): 'one of our top picks from last week's B. Riley MMV Summit'

Tue, 21 Jul 2026 05:16:13 -0400

B.Riley analyst Madison El-Saadi reiterated a Buy rating and $5.00 price target on Ovid Therapeutics Inc (NASDAQ: OVID).

The analyst comments "We reiterate our Buy rating and $5 PT on OVID, one of our top picks from last week's B. Riley MMV Summit (7/16 fireside and panel with CEO Meg Alexander), and continue to view the risk/ reward as compelling against a 39% YTD move vs XBI 27%. We see the dense stack of YE26- to-early-27 readouts across OV329 and KCC2 as sufficient to unlock the next leg of the story. The asymmetric re-rating drivers are, in our view: (1) OV329

B.Riley on Ovid Therapeutics Inc (OVID): 'one of our top picks from last week's B. Riley MMV Summit'

Tue, 21 Jul 2026 05:16:13 -0400

B.Riley analyst Madison El-Saadi reiterated a Buy rating and $5.00 price target on Ovid Therapeutics Inc (NASDAQ: OVID).

Form 4 Ovid Therapeutics Inc. For: Jul 06 Filed by: Carter Charles Ross

Wed, 08 Jul 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260708/26747955.html

Form 4 Ovid Therapeutics Inc. For: Jul 06 Filed by: Carter Charles Ross

Wed, 08 Jul 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260708/26747955.html

Form 3 Ovid Therapeutics Inc. For: Jul 06 Filed by: Carter Charles Ross

Wed, 08 Jul 2026 16:28:00 -0400

si-local-file:///var/storage/secattach/20260708/26747879.html

Form 3 Ovid Therapeutics Inc. For: Jul 06 Filed by: Carter Charles Ross

Wed, 08 Jul 2026 16:28:00 -0400

si-local-file:///var/storage/secattach/20260708/26747879.html

Form SCHEDULE 13G/A Ovid Therapeutics Inc. Filed by: FEDERATED HERMES, INC.

Wed, 08 Jul 2026 07:55:00 -0400

si-local-file:///var/storage/secattach/20260708/26744378.html

Form SCHEDULE 13G/A Ovid Therapeutics Inc. Filed by: FEDERATED HERMES, INC.

Wed, 08 Jul 2026 07:55:00 -0400

si-local-file:///var/storage/secattach/20260708/26744378.html

Form 8-K Ovid Therapeutics Inc. For: Jul 05

Wed, 08 Jul 2026 07:04:00 -0400

si-local-file:///var/storage/secattach/20260708/26744171.html

Form 8-K Ovid Therapeutics Inc. For: Jul 05

Wed, 08 Jul 2026 07:04:00 -0400

si-local-file:///var/storage/secattach/20260708/26744171.html

Ovid Therapeutics names new CFO and CBO in leadership reshuffle

Wed, 08 Jul 2026 07:02:50 -0400

Ovid Therapeutics Inc. (Nasdaq: OVID) announced several executive leadership changes, including new appointments and internal promotions, according to a press release from the New York-based biopharmaceutical company.

Kevin Norrett will join as Chief Business Officer, bringing more than 30 years of life sciences experience. He most recently served as Chief Business Officer at Soleno Therapeutics, where he led the company's acquisition by Neurocrine Biosciences. He has also held roles at Codexis, Sierra Oncology, Aimmune Therapeutics, Exelixis, and Genentech.

Charles Carter has been promoted to Chief Financial Officer from Senior Vice President of Finance and Financial Planning. He succeeds Jeffrey Rona, who will

Ovid Therapeutics names new CFO and CBO in leadership reshuffle

Wed, 08 Jul 2026 07:02:50 -0400

Charles Carter has been promoted to Chief Financial Officer from Senior Vice President of Finance and Financial Planning. He succeeds Jeffrey Rona, who will

Ovid Therapeutics Strengthens Executive Leadership Team to Support Continued Pipeline Progress and Next Phase of Development

Wed, 08 Jul 2026 07:00:00 -0400

Kevin Norrett, a proven leader in advancing corporate strategy through value-creating transactions, will be appointed as Chief Business Officer
Charles Carter promoted to Chief Financial Officer, reflecting his strong leadership and oversight of Ovid’s financial operations, following Jeffrey Rona’s transition to an advisory role
Eliseo Salinas, MD, joined as Executive R&D Advisor, building on a distinguished career leading the development of multiple, breakthrough neurologic and psychiatric medicines
Victoria Fort promoted to Chief Strategy Officer, reflecting her leadership in advancing Ovid’s corporate strategy and investor relations

NEW YORK, July

Ovid Therapeutics Strengthens Executive Leadership Team to Support Continued Pipeline Progress and Next Phase of Development

Wed, 08 Jul 2026 07:00:00 -0400

Kevin Norrett, a proven leader in advancing corporate strategy through value-creating transactions, will be appointed as Chief Business Officer
Charles Carter promoted to Chief Financial Officer, reflecting his strong leadership and oversight of Ovid’s financial operations, following Jeffrey Rona’s transition to an advisory role
Eliseo Salinas, MD, joined as Executive R&D Advisor, building on a distinguished career leading the development of multiple, breakthrough neurologic and psychiatric medicines
Victoria Fort promoted to Chief Strategy Officer, reflecting her leadership in advancing Ovid’s corporate strategy and investor relations

NEW YORK, July

Form 4 Ovid Therapeutics Inc. For: Jun 15 Filed by: Greka Anna

Wed, 17 Jun 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260617/26660231.html

Form 4 Ovid Therapeutics Inc. For: Jun 15 Filed by: Greka Anna

Wed, 17 Jun 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260617/26660231.html

Form 3 Ovid Therapeutics Inc. For: Jun 15 Filed by: Greka Anna

Wed, 17 Jun 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260617/26660194.html

Form 3 Ovid Therapeutics Inc. For: Jun 15 Filed by: Greka Anna

Wed, 17 Jun 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260617/26660194.html

Form 8-K Ovid Therapeutics Inc. For: Jun 11

Thu, 11 Jun 2026 09:03:00 -0400

si-local-file:///var/storage/secattach/20260611/26633489.html

Form 8-K Ovid Therapeutics Inc. For: Jun 11

Thu, 11 Jun 2026 09:03:00 -0400

si-local-file:///var/storage/secattach/20260611/26633489.html

Ovid Therapeutics to Participate in Upcoming Investor Conferences

Thu, 04 Jun 2026 07:00:00 -0400

NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today announced that the Company’s management will participate in two upcoming investor conferences:

Oppenheimer CNS & Neuro-Muscular Summit – Wednesday, June 10 at 3:45 pm ET
H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference – Monday, June 15

A webcast of the presentations can be accessed through the Events & Presentations section of the company’s website at investors.ovidrx.com. An archived

Ovid Therapeutics to Participate in Upcoming Investor Conferences

Thu, 04 Jun 2026 07:00:00 -0400

Oppenheimer CNS & Neuro-Muscular Summit – Wednesday, June 10 at 3:45 pm ET
H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference – Monday, June 15

A webcast of the presentations can be accessed through the Events & Presentations section of the company’s website at investors.ovidrx.com. An archived

Form 8-K Ovid Therapeutics Inc. For: May 29

Wed, 03 Jun 2026 07:03:00 -0400

si-local-file:///var/storage/secattach/20260603/26595290.html

Form 8-K Ovid Therapeutics Inc. For: May 29

Wed, 03 Jun 2026 07:03:00 -0400

si-local-file:///var/storage/secattach/20260603/26595290.html

Ovid Therapeutics names Anna Greka to board of directors

Wed, 03 Jun 2026 07:00:16 -0400

Ovid Therapeutics Inc. (NASDAQ: OVID) announced the appointment of Anna Greka, M.D., Ph.D., to its board of directors, effective June 15, 2026.

Greka serves as a core institute member at the Broad Institute of MIT and Harvard and is a professor of medicine at Harvard Medical School and Mass General Brigham. She currently leads the Ladders to Cures Scientific Accelerator, an organization focused on translating fundamental discoveries into therapies.

The physician-scientist has founded and advised multiple biotechnology companies, including Goldfinch Bio, which was acquired by Bristol Myers Squibb, and a company recently acquired by AstraZeneca. She holds over 25 years of experience